KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Equity (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Return on Equity for 15 consecutive years, with 1.56% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Equity fell 222.0% year-over-year to 1.56%, compared with a TTM value of 1.56% through Jun 2025, down 222.0%, and an annual FY2024 reading of 3.62%, up 130.0% over the prior year.
  • Return on Equity was 1.56% for Q2 2025 at Alnylam Pharmaceuticals, up from 2.53% in the prior quarter.
  • Across five years, Return on Equity topped out at 10.02% in Q4 2022 and bottomed at 22.69% in Q3 2024.
  • Average Return on Equity over 5 years is 2.17%, with a median of 1.02% recorded in 2021.
  • The sharpest move saw Return on Equity soared 2359bps in 2023, then plummeted -2447bps in 2024.
  • Year by year, Return on Equity stood at 1.27% in 2021, then skyrocketed by 889bps to 10.02% in 2022, then plummeted by -77bps to 2.28% in 2023, then tumbled by -346bps to 5.59% in 2024, then soared by 72bps to 1.56% in 2025.
  • Business Quant data shows Return on Equity for ALNY at 1.56% in Q2 2025, 2.53% in Q1 2025, and 5.59% in Q4 2024.